Cancer Cachexia: Early diagnosis and multimodal strategies of care
After participating you can claim your CME credit here: https://forms.gle/wTKztxgF56PHBWDQA
Accreditation: 0.25 AMA PRA Category 1 Credits™
Learning objectives
**
- Recognize and diagnose CC earlier and more consistently across cancer types:
- Apply validated diagnostic frameworks (e.g., criteria including ≥5% weight loss, low BMI, sarcopenia) to identify cachexia in its early stages.
- Integrate practical bedside tools (e.g., handgrip strength, mid-arm circumference) and EMR-based documentation practices into routine assessments.
- Identify and overcome barriers to cachexia screening, including patient communication concerns and inconsistent team workflows.
- Implement evidence-based, multimodal strategies to support appetite, lean body mass, and physical function in patients with CC:
- Coordinate multidisciplinary care that combines nutritional interventions, physical activity programs, and pharmacologic therapies tailored to patient status.
- Engage dietitians, physiotherapists, and palliative care teams to deliver individualized, stage-appropriate cachexia management.
- Monitor intervention outcomes through functional measures (e.g., muscle mass, mobility) and adjust care plans accordingly.
- Anticipate emerging therapeutic innovation in cancer cachexia and support appropriate clinical trial engagement:
- Evaluate the mechanism of GDF-15 and its relevance to the pathophysiology and progression of cancer cachexia.
- Identify patients who may be appropriate candidates for participation in clinical trials evaluating emerging therapeutic targets.
- Incorporate awareness of evolving treatment strategies into multidisciplinary care planning, while maintaining alignment with current evidence and regulatory standards.
This program is supported by an independent education grant from Pfizer. This online education program has been designed for healthcare professionals globally.
Continuing Education Information
This continuing education activity will be provided by Current Concepts Institute (CCI) and MedAll. Physicians, Nurse Practitioners, and Physician Assistants will be eligible for AMA PRA Category 1 Credit™; Nurses for ANCC Contact Hours. A statement of participation is available for other healthcare professionals.
Disclosures Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.
Dr. Barry J. A. Laird has disclosed financial relationships within the past 24 months with the following ineligible companies: Artelo, Endevica Bio, Pfizer, Catalym, and Abbott, serving in advisory or investigator roles. He does not intend to reference any unlabeled or unapproved uses of products during the presentation.
Dr. Jeffrey Crawford has disclosed financial relationships within the past 24 months with the following ineligible companies: Actimed, Gen Sci, Pfizer, Tensegrity, AstraZeneca, BioAtla, and Pharmacosmos. These relationships include roles such as scientific advisor, steering committee member, clinical trial site participant, and DSMB member. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. This activity includes reference to non-FDA uses of drug products and/or devices and their unlabelled indications.
CCI/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.
Activity Accreditation for Health Professions
Physicians
0.25 AMA PRA Category 1 Credits™ are available for this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.
Current Concepts Institute designates this online activity a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This continuing education activity is active starting 30th October 2025 and will expire on 31st December 2026. Estimated time to complete this activity: 15 minutes.
Other Professionals All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Participation Costs There is no cost to participate in this program.
This program is supported by an independent education grant from Pfizer. This online education program has been designed for healthcare professionals globally.
Continuing Education Information
This continuing education activity will be provided by Current Concepts Institute (CCI) and MedAll. Physicians, Nurse Practitioners, and Physician Assistants will be eligible for AMA PRA Category 1 Credit™; Nurses for ANCC Contact Hours. A statement of participation is available for other healthcare professionals.
Disclosures Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.
Dr. Barry J. A. Laird has disclosed financial relationships within the past 24 months with the following ineligible companies: Artelo, Endevica Bio, Pfizer, Catalym, and Abbott, serving in advisory or investigator roles. He does not intend to reference any unlabeled or unapproved uses of products during the presentation.
Dr. Jeffrey Crawford has disclosed financial relationships within the past 24 months with the following ineligible companies: Actimed, Gen Sci, Pfizer, Tensegrity, AstraZeneca, BioAtla, and Pharmacosmos. These relationships include roles such as scientific advisor, steering committee member, clinical trial site participant, and DSMB member. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. This activity includes reference to non-FDA uses of drug products and/or devices and their unlabelled indications.
CCI/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.
Activity Accreditation for Health Professions
Physicians
0.25 AMA PRA Category 1 Credits™ are available for this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.
Current Concepts Institute designates this online activity a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This continuing education activity is active starting 30th October 2025 and will expire on 31st December 2026. Estimated time to complete this activity: 15 minutes.
Other Professionals All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Participation Costs There is no cost to participate in this program.